Novo Nordisk Shows It Is Ready To Extend Its Obesity Portfolio

Novel Oral Obesity Drug Shows Promise

During a capital markets day, the company highlighted Phase I weight loss data for its novel oral obesity drug amycretin, which could work in a complementary fashion to GLP-1s. 

scale
Novo Nordisk revealed new obesity drug data • Source: Shutterstock

Novo Nordisk A/S revealed encouraging efficacy data for a novel oral obesity medicine during a capital market day on 7 March, intriguing investors who are aware the company will need to deliver next-generation advances in obesity to maintain its leadership position in the competitive therapeutic area.

Key Takeaways
  • Novo Nordisk revealed encouraging efficacy data for a novel oral obesity medicine amycretin during a capital market day.

Amycretin, which is a co-agonist of the GLP-1 and amylin receptors, could be a complementary mode of action to Novo...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Alimentary/Metabolic

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By 

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.